CDH3 and breast carcinoma: Considering that GBMs are known for their remarkable invasiveness capacity [35], and since P‐cadherin has been shown to impact cell invasion in different tumors (e.g., melanoma [20, 21] and breast cancer [18]), we also evaluated how P‐cadherin affects this cancer hallmark feature by three‐dimensional invasion assays (Fig. 2D).